Cost and effectiveness of therapy for wet age-related macular
degeneration in routine clinical practice

J 2013

Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice

STUDNIČKA, Jan, Barbora ŘÍHOVÁ, Eva RENCOVÁ, Pavel ROZSÍVAL, Zora DUBSKÁ et. al.

Základní údaje

Originální název

Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice

Autoři

STUDNIČKA, Jan (203 Česká republika), Barbora ŘÍHOVÁ (203 Česká republika, garant, domácí), Eva RENCOVÁ (203 Česká republika), Pavel ROZSÍVAL (203 Česká republika), Zora DUBSKÁ (203 Česká republika), Oldřich CHRAPEK (203 Česká republika), Petr KOLÁŘ (203 Česká republika), Vít KANDRNAL (203 Česká republika, domácí), Regina DEMLOVÁ (203 Česká republika, domácí), Šárka PITROVÁ (203 Česká republika) a Jiří ŘEHÁK (203 Česká republika)

Vydání

Ophthalmologica, BERN, KARGER, 2013, 0030-3755

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.867

Kód RIV

RIV/00216224:14110/13:00069347

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1159/000350802

UT WoS

000321466100005

Klíčová slova anglicky

Age-related macular degeneration; Choroidal neovascular membrane; Ranibizumab; Pegaptanib; Photodynamic therapy with verteporfin; Cost-effectiveness

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 11. 2019 12:42, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: Evaluation of the cost and effectiveness of therapy for patients with the wet form of age-related macular degeneration (AMD) in routine clinical practice. Methods: A retrospective multicentre evaluation of changes in the best-corrected visual acuity in applied kinds of therapy and a comparison with the cost of individual therapeutic procedures. Results: An overall total of 788 eyes of 763 patients with an average age of 73.2 +/- 8.6 years was evaluated for a 1-year minimum period. In the ranibizumab and pegaptanib therapy groups, a reduction of 1.3 letters (p = 0.303) and 1.4 letters (p = 0.197) was found, respectively. In the group of photodynannic therapy (PDT) with verteporfin, a reduction of 5.2 letters was achieved (p < 0.001). Under the conditions of routine practice in the Czech Republic, the annual cost is highest (EUR 5,467.63/patient) in patients with pegaptanib therapy. The annual cost in patients with ranibizumab therapy is lower by EUR 1,220.16. The cost is nearly half (EUR 2,783.65) in the group treated with PDT with verteporfin. Conclusion: An initiation of AMD therapy by ranibizumab is cost-effective as compared to pegaptanib. Both ranibizumab and pegaptanib are significantly more efficient as compared to PDT with verteporfin. Therapy with ranibizunnab and pegaptanib, as compared to PDT with verteporfin, prevents the loss of 1 line of vision on the ETDRS chart for EUR 1,225.98 and 2,286.18, respectively.

Citovat

STUDNIČKA, Jan, Barbora ŘÍHOVÁ, Eva RENCOVÁ, Pavel ROZSÍVAL, Zora DUBSKÁ, Oldřich CHRAPEK, Petr KOLÁŘ, Vít KANDRNAL, Regina DEMLOVÁ, Šárka PITROVÁ a Jiří ŘEHÁK. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice. Ophthalmologica. BERN: KARGER, 2013, roč. 230, č. 1, s. 34-42. ISSN 0030-3755. Dostupné z: https://dx.doi.org/10.1159/000350802.

@article{1122733,
   author = {Studnička, Jan and Říhová, Barbora and Rencová, Eva and Rozsíval, Pavel and Dubská, Zora and Chrapek, Oldřich and Kolář, Petr and Kandrnal, Vít and Demlová, Regina and Pitrová, Šárka and Řehák, Jiří},
   article_location = {BERN},
   article_number = {1},
   doi = {http://dx.doi.org/10.1159/000350802},
   keywords = {Age-related macular degeneration; Choroidal neovascular membrane; Ranibizumab; Pegaptanib; Photodynamic therapy with verteporfin; Cost-effectiveness},
   language = {eng},
   issn = {0030-3755},
   journal = {Ophthalmologica},
   title = {Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice},
   url = {http://www.karger.com/Article/Abstract/350802},
   volume = {230},
   year = {2013}
}

TY  - JOUR
ID  - 1122733
AU  - Studnička, Jan - Říhová, Barbora - Rencová, Eva - Rozsíval, Pavel - Dubská, Zora - Chrapek, Oldřich - Kolář, Petr - Kandrnal, Vít - Demlová, Regina - Pitrová, Šárka - Řehák, Jiří
PY  - 2013
TI  - Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice
JF  - Ophthalmologica
VL  - 230
IS  - 1
SP  - 34-42
EP  - 34-42
PB  - KARGER
SN  - 00303755
KW  - Age-related macular degeneration
KW  - Choroidal neovascular membrane
KW  - Ranibizumab
KW  - Pegaptanib
KW  - Photodynamic therapy with verteporfin
KW  - Cost-effectiveness
UR  - http://www.karger.com/Article/Abstract/350802
N2  - Purpose: Evaluation of the cost and effectiveness of therapy for patients with the wet form of age-related macular degeneration (AMD) in routine clinical practice. Methods: A retrospective multicentre evaluation of changes in the best-corrected visual acuity in applied kinds of therapy and a comparison with the cost of individual therapeutic procedures. Results: An overall total of 788 eyes of 763 patients with an average age of 73.2 +/- 8.6 years was evaluated for a 1-year minimum period. In the ranibizumab and pegaptanib therapy groups, a reduction of 1.3 letters (p = 0.303) and 1.4 letters (p = 0.197) was found, respectively. In the group of photodynannic therapy (PDT) with verteporfin, a reduction of 5.2 letters was achieved (p < 0.001). Under the conditions of routine practice in the Czech Republic, the annual cost is highest (EUR 5,467.63/patient) in patients with pegaptanib therapy. The annual cost in patients with ranibizumab therapy is lower by EUR 1,220.16. The cost is nearly half (EUR 2,783.65) in the group treated with PDT with verteporfin. Conclusion: An initiation of AMD therapy by ranibizumab is cost-effective as compared to pegaptanib. Both ranibizumab and pegaptanib are significantly more efficient as compared to PDT with verteporfin. Therapy with ranibizunnab and pegaptanib, as compared to PDT with verteporfin, prevents the loss of 1 line of vision on the ETDRS chart for EUR 1,225.98 and 2,286.18, respectively.
ER  -

STUDNIČKA, Jan, Barbora ŘÍHOVÁ, Eva RENCOVÁ, Pavel ROZSÍVAL, Zora DUBSKÁ, Oldřich CHRAPEK, Petr KOLÁŘ, Vít KANDRNAL, Regina DEMLOVÁ, Šárka PITROVÁ a Jiří ŘEHÁK. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice. \textit{Ophthalmologica}. BERN: KARGER, 2013, roč.~230, č.~1, s.~34-42. ISSN~0030-3755. Dostupné z: https://dx.doi.org/10.1159/000350802.

Podrobný výpis o publikaci